Buy One-Alpha

One-Alpha

What is One-Alpha?

One-Alpha is a prescription medication that contains alfacalcidol as its active ingredient. It belongs to the bone-health therapeutic class and is supplied as a 0.25 µg capsule. In the United Kingdom, One-Alpha is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) and is available only with a prescription. The product is used to manage conditions that involve disturbed calcium metabolism and bone turnover.

How One-Alpha Works in the Body

Alfacalcidol is a synthetic analogue of vitamin D₃ that is already hydroxylated at the 1-alpha position. After oral administration, it is rapidly converted by the liver into calcitriol (1,25-dihydroxy-vitamin D₃), the hormonally active form of vitamin D. Calcitriol then:

• Enhances intestinal calcium and phosphate absorption by stimulating the synthesis of calcium-binding proteins.
• Promotes bone mineralisation through its actions on osteoblasts and osteoclasts.
• Regulates parathyroid hormone (PTH) secretion, helping to normalise calcium levels in conditions such as secondary hyperparathyroidism.

Because alfacalcidol bypasses the renal 1-alpha-hydroxylation step, it is particularly useful in patients with impaired kidney function where conversion of native vitamin D to calcitriol is reduced.

The onset of action usually occurs within a few days, with peak biochemical effects on serum calcium observed after 1-2 weeks of consistent dosing. The biological half-life of calcitriol is approximately 15 hours, resulting in a relatively short duration of effect that allows dose adjustments based on laboratory monitoring.

Conditions Treated with One-Alpha

One-Alpha is authorised in the UK for the following indications:

• Hypocalcaemia secondary to hypoparathyroidism - to raise and maintain serum calcium levels when endogenous PTH is insufficient.
• Renal osteodystrophy - a bone disorder caused by chronic kidney disease (CKD) that leads to disturbed calcium-phosphate balance and secondary hyperparathyroidism.
• Osteoporosis in patients with chronic kidney disease - to improve bone mineral density where conventional vitamin D therapy may be ineffective.

These uses are supported by MHRA-approved product information and clinical guidelines for managing calcium disorders in the context of impaired renal function.

Patient Suitability and Contraindications

Ideal candidates

• Adults with documented hypocalcaemia or secondary hyperparathyroidism related to CKD.
• Patients requiring vitamin D supplementation when renal conversion to calcitriol is compromised.

Absolute contraindications

• Known hypersensitivity to alfacalcidol or any excipients in the capsule.
• Uncontrolled hypercalcaemia (serum calcium above the normal reference range).
• Granulomatous diseases such as sarcoidosis or tuberculosis, where vitamin D metabolism is dysregulated.
• Pregnancy and lactation are contraindicated unless the benefits clearly outweigh the risks and a specialist advises otherwise.

Relative contraindications

• Severe renal impairment not covered by the approved indication (e.g., eGFR < 15 mL/min/1.73 m² without CKD-related bone disease).
• Concomitant use of drugs that increase calcium levels (e.g., thiazide diuretics) without careful monitoring.
• Pre-existing hypervitaminosis D.

Special populations such as the elderly may require dose adjustments based on serum calcium and renal function.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Nausea or vomiting - often mild and transient.
• Headache - typically resolves without intervention.
• Dry mouth - may improve with adequate hydration.

Serious Adverse Events

• Severe hypercalcaemia - characterised by thirst, polyuria, confusion, cardiac arrhythmia; requires immediate medical attention.
• Renal calculi - due to prolonged high calcium excretion.
• Hypotension (rare) linked to abrupt shifts in fluid balance.

Drug Interactions

• Thiazide diuretics - can potentiate hypercalcaemia; monitor serum calcium closely.
• Calcium supplements - additive effect on calcium levels; dose adjustment may be necessary.
• Digitalis (digoxin) - hypercalcaemia can increase the risk of digoxin toxicity.
• CYP450-interacting drugs - alfacalcidol is metabolised in the liver; strong inducers or inhibitors may alter its activity, though clinically significant interactions are uncommon.

Food and Lifestyle Interactions

• No specific food restrictions, but high-calcium diets may amplify calcium-raising effects.
• Alcohol consumption does not significantly affect alfacalcidol pharmacokinetics but can contribute to dehydration, potentially worsening hypercalcaemia.
• Driving or operating machinery is not impaired by One-Alpha; however, severe hypercalcaemia may cause dizziness or confusion, warranting caution.

Note: Patients should inform their healthcare provider of all medicines, supplements, and herbal products before starting One-Alpha.

How to Take One-Alpha

• Standard dosing: One-Alpha 0.25 µg capsule taken once daily, preferably with a meal to enhance absorption.
• Dose adjustments: Based on serum calcium, phosphate, and PTH levels; the prescriber may increase the dose in increments of 0.25 µg but should not exceed the maximum recommended dose without specialist input.
• Renal impairment: In patients with severe CKD (eGFR < 30 mL/min/1.73 m²), a lower starting dose (e.g., 0.125 µg) may be considered, with frequent monitoring.
• Elderly patients: Start with the standard dose but assess calcium levels after 2 weeks; adjust as needed.
• Missed dose: Take the missed dose as soon as remembered on the same day; do not double the dose the following day.
• Overdose: Symptoms include nausea, vomiting, polyuria, and muscle weakness. Seek urgent medical care; treatment focuses on hydration, diuretics, and, in severe cases, intravenous bisphosphonates.
• Discontinuation: Generally, no tapering is required, but abrupt cessation may lead to a rapid decline in calcium levels; follow the prescriber’s guidance.

Monitoring and Follow-Up

• Baseline tests: Serum calcium, phosphate, alkaline phosphatase, creatinine, and 25-hydroxy-vitamin D.
• Routine monitoring: Re-check calcium and phosphate every 3 months during the first year, then every 6 months once stable.
• Additional assessments: Periodic PTH measurement in CKD patients; renal function tests as clinically indicated.
• When to contact a healthcare professional: Persistent symptoms of hypercalcaemia, new onset of kidney stones, or unexplained fatigue.

Storage and Handling

• Keep capsules in their original container, tightly closed, at room temperature (15-25 °C).
• Protect from moisture and direct sunlight.
• Do not use after the expiry date printed on the packaging.
• Dispose of unused medication in accordance with local pharmacy guidelines; do not flush capsules down the toilet.

Medication-Specific Glossary

Alfacalcidol

A synthetic 1-alpha-hydroxy vitamin D₃ analogue that is converted in the liver to calcitriol, the active hormonal form of vitamin D.

Calcitriol

1,25-dihydroxy-vitamin D₃, the biologically active metabolite that regulates calcium and phosphate homeostasis.

Renal Osteodystrophy

A spectrum of bone disorders that arise from chronic kidney disease-induced disturbances in mineral metabolism.

Hypercalcaemia

An elevated level of calcium in the blood, which can cause neurological, renal, and cardiac complications.

Medical Disclaimer

This article provides educational information about One-Alpha and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.